BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

BeOne Medicines Ltd.

ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S. ( ($TR:ONCSM) ) has shared an update. Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. has sig...

Oncosem Secures Five-Year Chemotherapy Drug Preparation Contract in Istanbul

In a report released on August 11, from CICC maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK$266.00. The company’s shares...

CICC Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)

Onco-Innovations Ltd. ( ($TSE:ONCO) ) has issued an update. Onco-Innovations reported that Nanosoft Polymers has identified a non-tin catalyst to i...

Onco-Innovations Advances ONC010 Manufacturing and Polymer Development for Future Clinical Trials

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines’ partner BeiGene has completed a Phase 1 study titled “...

Subcutaneous Tislelizumab Trial Completion Signals Next Steps for BeOne Medicines and BeiGene

ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S. ( ($TR:ONCSM) ) has shared an announcement. Oncosem Onkolojik Sistemler has applied to the Capit...

Oncosem Onkolojik Sistemler Launches Major Bonus Capital Increase from Internal Reserves

In a report released yesterday, from BOCOM International Holdings Company maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK...

BOCOM International Holdings Company Keeps Their Buy Rating on BeOne Medicines Ltd (6160)

In a report released on August 6, from CICC maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK$266.00. The company’s shares ...

BeOne Medicines Ltd (6160) Gets a Buy from CICC

UOB Kay Hian analyst maintained a Buy rating on BeOne Medicines Ltd on August 6 and set a price target of HK$265.00. The company’s shares closed ye...

UOB Kay Hian Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)

In a report released on August 6, David Li from Bank of America Securities maintained a Buy rating on BeOne Medicines Ltd, with a price target of H...

Bank of America Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BeOne Medicines (ONC) and Doximity (DOCS). BeOne Medicines (ONC) ...

Analysts Conflicted on These Healthcare Names: BeOne Medicines (ONC) and Doximity (DOCS)

In a report released yesterday, Michael Schmidt from Guggenheim maintained a Buy rating on BeOne Medicines, with a price target of $430.00. The com...

Guggenheim Sticks to Its Buy Rating for BeOne Medicines (ONC)

Barclays analyst Etzer Darout maintained a Buy rating on BeOne Medicines today and set a price target of $407.00. According to TipRanks, Darout is ...

Barclays Remains a Buy on BeOne Medicines (ONC)

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines (ONC) is launching a Phase 2 study in Japan to test dif...

BeOne Medicines Targets Esophageal Cancer With New Tislelizumab Trial in Japan

Nomura analyst maintained a Buy rating on BeOne Medicines Ltd on July 24 and set a price target of HK$270.74. The company’s shares closed yesterday...

BeOne Medicines Ltd (6160) Gets a Buy from Nomura

Oncolytics Biotech ( ($ONCY) ) has issued an update. On July 20, 2026, Oncolytics Biotech disclosed that it received a notice from Nasdaq indicatin...

Oncolytics Biotech Faces Nasdaq Minimum Bid Price Noncompliance

RBC Capital analyst Piral Dadhania maintained a Hold rating on Moncler S.p.A. on July 22 and set a price target of €59.00. The company’s shares clo...

Moncler S.p.A. (0QII) Gets a Hold from RBC Capital

In a report released today, Carole Madjo from Barclays maintained a Buy rating on Moncler S.p.A., with a price target of €62.00. According to TipRa...

Barclays Remains a Buy on Moncler S.p.A. (0QII)

The latest update is out from Oncolytics Biotech ( ($ONCY) ). On July 20, 2026, Oncolytics Biotech announced that the U.S. Food and Drug Administra...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ONC	$359.67	+3.51%	239.08K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ONC	$359.67	+3.5%	239.08K
3
4
5
6

ONC

Get BeOne Medicines Ltd. Data in Excel

Get BeOne Medicines Ltd. Data in Excel